These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33884929)

  • 21. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.
    Fizazi K; Scher HI; Miller K; Basch E; Sternberg CN; Cella D; Forer D; Hirmand M; de Bono JS
    Lancet Oncol; 2014 Sep; 15(10):1147-56. PubMed ID: 25104109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
    Shore ND; Chowdhury S; Villers A; Klotz L; Siemens DR; Phung D; van Os S; Hasabou N; Wang F; Bhattacharya S; Heidenreich A
    Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL, Hussain M, University of Michigan, Ann Arbor, MI. J Clin Oncol 2013;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1848. PubMed ID: 24210087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Pregnenolone vs Placebo on Self-reported Chronic Low Back Pain Among US Military Veterans: A Randomized Clinical Trial.
    Naylor JC; Kilts JD; Shampine LJ; Parke GJ; Wagner HR; Szabo ST; Smith KD; Allen TB; Telford-Marx EG; Dunn CE; Cuffe BT; O'Loughlin SH; Marx CE
    JAMA Netw Open; 2020 Mar; 3(3):e200287. PubMed ID: 32119096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
    Loriot Y; Miller K; Sternberg CN; Fizazi K; De Bono JS; Chowdhury S; Higano CS; Noonberg S; Holmstrom S; Mansbach H; Perabo FG; Phung D; Ivanescu C; Skaltsa K; Beer TM; Tombal B
    Lancet Oncol; 2015 May; 16(5):509-21. PubMed ID: 25888263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.
    Maughan BL; Suzman DL; Luber B; Wang H; Glavaris S; Hughes R; Sullivan R; Harb R; Boudadi K; Paller C; Eisenberger M; Demarzo A; Ross A; Antonarakis ES
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1297-1304. PubMed ID: 27826729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week.
    Shi Q; Wang XS; Mendoza TR; Pandya KJ; Cleeland CS
    J Pain Symptom Manage; 2009 Feb; 37(2):168-74. PubMed ID: 18676116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
    Yu EY; Ellard SL; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME; Chi KN
    Invest New Drugs; 2018 Apr; 36(2):278-287. PubMed ID: 29250742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
    Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
    JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reliability and validity of individual and composite recall pain measures in patients with cancer.
    Jensen MP; Wang W; Potts SL; Gould EM
    Pain Med; 2012 Oct; 13(10):1284-91. PubMed ID: 22925436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union.
    Clark MJ; Harris N; Griebsch I; Kaschinski D; Copley-Merriman C
    Health Qual Life Outcomes; 2014 Jul; 12():104. PubMed ID: 24989428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
    Chi KN; Higano CS; Blumenstein B; Ferrero JM; Reeves J; Feyerabend S; Gravis G; Merseburger AS; Stenzl A; Bergman AM; Mukherjee SD; Zalewski P; Saad F; Jacobs C; Gleave M; de Bono JS
    Lancet Oncol; 2017 Apr; 18(4):473-485. PubMed ID: 28283282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab).
    Yachnin J; Gilje B; Thon K; Johansson H; Brandberg Y; Panaretakis T; Ullén A
    Eur J Cancer; 2018 Jul; 97():33-40. PubMed ID: 29685343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using multiple daily pain ratings to improve reliability and assay sensitivity: how many is enough?
    Heapy A; Dziura J; Buta E; Goulet J; Kulas JF; Kerns RD
    J Pain; 2014 Dec; 15(12):1360-5. PubMed ID: 25283469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).
    Dorff TB; Quinn DI; Pinski JK; Goldkorn A; Sadeghi S; Tsao-Wei D; Groshen S; Kuhn P; Gross ME
    Clin Genitourin Cancer; 2019 Aug; 17(4):241-247.e1. PubMed ID: 31227432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
    Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
    Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.